Akari Therapeutics Granted Nomacopan Orphan Drug Designation From The European Commission For Treatment In Hematopoietic Stem Cell Transplantation
Portfolio Pulse from Happy Mohamed
Akari Therapeutics (NASDAQ:AKTX) has been granted orphan drug designation by the European Commission for nomacopan, a treatment in hematopoietic stem cell transplantation. This follows a positive opinion from the European Medicines Agency in June. The company is currently conducting a Phase 3 study of nomacopan in pediatric HSCT-TMA and plans to begin a Phase 3 trial in adult HSCT-TMA in 2024. The orphan drug designation is in addition to the Rare Pediatric Disease, Orphan Drug, and Fast Track designations already granted by the U.S. FDA.
July 27, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akari Therapeutics has been granted orphan drug designation for nomacopan by the European Commission, which could potentially open up a new market for the company. This could have a positive impact on the company's stock in the short term.
The orphan drug designation is a significant regulatory milestone that could potentially open up a new market for Akari's nomacopan. This could lead to increased revenues for the company in the future, which would likely be viewed positively by investors and could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100